Skip to main
  1. Stocks
  2. AIM ImmunoTech Inc
  3. Forecast
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is attractive because it is concentrating its limited clinical and financial resources on late-stage pancreatic cancer, a disease with more than 450,000 deaths worldwide as recently as 2022 and substantial unmet need. The company’s DURIPANC Phase 2 study, run with AstraZeneca and Erasmus MC, has enrolled 18 subjects, with key clinical benefit data expected in Q1 2027 and overall survival data in Q3 2027, giving investors multiple near-term catalysts. Although AIM remains early stage with a Q1 2026 net loss of $3.0 million, $6 million in cash, and $4 million in debt, positive safety and efficacy signals, plus other ongoing trials, support a high-risk, high-reward outlook.

Bears say

AIM ImmunoTech is pressured by its clinical-stage profile, which keeps revenue minimal while exposing the company to heavy reliance on successful trial outcomes, regulatory approvals, and eventual commercialization of Ampligen and Alferon N. Its Q2 2026 results, reported on August 10, showed a $7 million net loss, or $(0.43) per share, materially worse than the $(0.12) to $(0.17) estimates, underscoring weak operating leverage and continued earnings shortfall. The outlook is further weakened by balance sheet and liquidity risk, reimbursement uncertainty, competitive pressures, and the possibility that changing macroeconomic conditions and biotech investor sentiment could keep funding and valuation under pressure.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

AIM Analyst Forecast & Price Prediction

Get the latest AIM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AIM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


AIM Analyst Forecast & Price Prediction

Get the latest AIM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AIM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AIM stock data and trends